Eliquis Gets NICE Final Nod But Fails to Outrun The Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has cleared a path for Bristol-Myers Squibb’s Eliquis to be included on the British National Health System, but said the data supplied were not robust enough to differentiate the drug from its competition.
You may also be interested in...
Adapting HTA To A Value-Based Approach: A Conversation With ABPI's Stephen Whitehead
The Association of the British Pharmaceutical Industry's chief executive says a focus on drug value rather than cost, and an adaptive approach to health technology assessment are approaches that would encourage pharma innovation.
Sucampo’s Amitiza Flies Through NICE On Way To Wider European Review
NICE has recommended Sucampo's Amitiza in its full indication for chronic idiopathic constipation without even putting it out for public consultation.
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.